NAV

Triacetin

This drug entry is astuband has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Triacetinis an acetylating agent indicated in the treatment of ringworm.

Generic Name
Triacetin
DrugBank Accession Number
DB16005
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
 3D
Similar Structures
Weight
Average: 218.205
Monoisotopic: 218.079038171
Chemical Formula
C9H14O6
Synonyms
  • 1,2,3-Propanetriol triacetate
  • Glyceryl triacetate
  • Triacetin
  • Triacetina
  • Triacetine
  • Triacetinum
External IDs
  • 203-051-9
  • E-1518
  • FEMA NO. 2007
  • INS NO.1518
  • nsc - 4796

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image
อัลเบอร์-ที Triacetin(20 g/100g)+Tolnaftate(2 g/100g) Ointment Topical บริษัท ยูนีซัน จำกัด 1984-12-06 Not applicable Thailand flag
อีซอน-ที Triacetin(20 g/100g)+Tolnaftate(2 g/100g) Solution Topical บริษัท ยูนีซัน จำกัด 1985-09-26 Not applicable Thailand flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
XHX3C3X673
CAS number
102-76-1
InChI Key
URAYPUMNDPQOKB-UHFFFAOYSA-N
InChI
InChI=1S/C9H14O6/c1-6(10)13-4-9(15-8(3)12)5-14-7(2)11/h9H,4-5H2,1-3H3
IUPAC Name
1,3-bis(acetyloxy)propan-2-yl acetate
SMILES
CC(=O)OCC(COC(C)=O)OC(C)=O

References

一般References
  1. FDA Thailand: Ezon-T (Tolnaftate, Triacetin) Topical Ointment [Link]
  2. FDA Thailand: Ezon-T (Tolnaftate, Triacetin) Topical Solution [Link]
Human Metabolome Database
HMDB0029592
ChemSpider
13835706
RxNav
10756
ChEBI
9661
ChEMBL
CHEMBL1489254
ZINC
ZINC000001530705
Wikipedia
Triacetin

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
2 Withdrawn Treatment Aspartoacylase/Canavan Disease/Deficiency Diseases/Infantile/Leukodystrophy, Spongiform 1
Not Available Unknown Status Treatment Canavan Disease 1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Form Route Strength
Ointment Topical
Solution Topical
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
预测性能
Property Value Source
Water Solubility 11.3 mg/mL ALOGPS
logP 0.4 ALOGPS
logP -0.52 Chemaxon
logS -1.3 ALOGPS
pKa (Strongest Basic) -6.5 Chemaxon
Physiological Charge 0 Chemaxon
Hydrogen Acceptor Count 3 Chemaxon
Hydrogen Donor Count 0 Chemaxon
Polar Surface Area 78.9 Å2 Chemaxon
Rotatable Bond Count 8 Chemaxon
Refractivity 47.97 m3·mol-1 Chemaxon
Polarizability 21.13 Å3 Chemaxon
Number of Rings 0 Chemaxon
Bioavailability 1 Chemaxon
Rule of Five Yes Chemaxon
Ghose Filter No Chemaxon
Veber's Rule No Chemaxon
MDDR-like Rule No Chemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at December 10, 2020 21:28 / Updated at May 05, 2021 20:32